China Sinopharm International Corporation

China pharmaceutical group corporation (hereinafter referred to as "sinopharm group") is a large pharmaceutical and health industry group directly managed by the state-owned assets supervision and administration commission of the state council.
The group owns 720 subsidiaries and 6 listed companies, covering all aspects of the medical and health industry. In terms of research and development, it has 2 academicians of the Chinese academy of engineering, 7 national research institutions and a number of outstanding researchers, and is a domestic leader in the research and development of chemical drugs and biological products. In terms of production, the whole industrial chain production base of biopharmaceutical, chemical and modern Chinese medicine has been established. The annual sales revenue of self-owned products exceeds 20 billion yuan, and the output of biological products ranks the fourth in the world. In terms of circulation, it has a medical distribution network covering 31 provinces, autonomous regions and municipalities in China and 30 distribution centers in line with the international level. It has nearly 3,000 medical retail terminals. In terms of engineering design, it has an engineering design institute with high reputation and wide influence in the industry, and its chief editor has participated in more than ten national and industrial codes, ranking first in the domestic pharmaceutical engineering design industry.
The group's operating revenue exceeded 350 billion yuan in 2017, ranking the 199th place in the fortune global 500 list released in July 2017.